Project title: Enlightenment of a new era of cancer therapy: prognostication, target selection, and subsequent therapy determined by the dual tumor-immune phenotype

Holbrook Kohrt, MD, PhD; Pamela Kunz, MD Stanford University Cancer Center

Holbrook Kohrt, MD, PhD; Pamela Kunz, MD
  • Status: Completed
  • Year(s): 2015
  • Research Type: Clinical
  • Primary Tumor Site: Other
  • Area of Inquiry: Clinical trials

General Description

The ultimate goal of this project is to identify tumor-immune biomarkers that represent prognostic, predictive, and therapeutically actionable targets in patients with neuroendocrine tumors. A tumor’s capacity to evade and suppress the immune response is a well-established hallmark of cancer. That harnessing the immune response could result in cure of a subset of patients with cancer is a revolution in cancer therapy. However, determining the potential of immunotherapy to be efficacious for patients with NETs necessitates an understanding of the tumor-immune phenotype which today remains unknown.

Research Objectives

  1. To characterize the tumor-immune phenotype including a comprehensive immune profile and tumor genome utilizing the Stanford neuroendocrine tumor tissue microarray that includes 1031 tumors from 690 neuroendocrine tumor patients.
  2. To (a) characterize the tumor-immune phenotype including a comprehensive immune profile and tumor genome in serial samples among 20 patients enrolled in a Stanford investigator-initiated clinical trial of intratumoral anti-CTLA4 (ipilimumab) immunotherapy with anti-PD-L1 (MPDL3280A) in patients with well-differentiated, progressive neuroendocrine tumors.

 

Additional Details

  • Grant Duration: 1 years
  • Awards: No information
« Back to all funded research projects